EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Longitudinal changes in cardiorenal risk scores after SGLT2 inhibitor initiation in patients with CKD with and without type 2 diabetes

Irene Capelli, Daniele Vetrano iD, Danilo Ribichini, Michele Provenzano iD, Sasha Albertini, Sabrina Berti iD, Ilirjana Sanfilippo, Valentina Vicennati, Uberto Pagotto iD, Gaetano La Manna iD, Giuseppe Cianciolo

Journal of Nephrology · 2026

DOI: 10.1093/joneph/aajag105 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nephrology, 2026. Verfasst von Irene Capelli und 10 weiteren Autor:innen. Beteiligte Einrichtung: Nephrology, Dialysis and Kidney Transplant Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Renal Insufficiency, Chronic, Cardiovascular Diseases. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Sodium–glucose cotransporter-2 inhibitors (SGLT2i) have become the standard of care in managing chronic kidney disease (CKD) and heart failure (HF), both in patients with and without type 2 diabetes mellitus (T2DM). Nonetheless, identifying those at persistent high cardiovascular (CV) and renal risk remains critical.

Methods

We conducted a retrospective, 1:1 propensity-matched cohort study involving 132 CKD patients (66 with T2D and 66 without). Participants were followed for 12 months after SGLT2i initiation. Cardiovascular and renal risk were assessed using three validated tools—PREVENT, SCORE2 with CKD Add-on (SCORE2-CKD), and Kidney Failure Risk Equation (KFRE)—calculated at baseline and at 12-month follow-up. Changes in risk scores were analyzed, and logistic regression was used to identify predictors of improvement.

Results

After 12 months, PREVENT scores declined significantly in the diabetic subgroup (Δ −2.95, P = .001), whereas non-diabetic patients showed no significant change (Δ −0.80, P = .396). SCORE2-CKD also decreased in diabetics (Δ −3.85, 95% CI −4.35 to −3.35, P = .023) but unexpectedly increased in non-diabetic patients (Δ + 3.25, P = .044). Importantly, individuals at higher baseline risk exhibited the most pronounced declines in both PREVENT and SCORE2-CKD. KFRE-derived renal risk decreased significantly in both groups. Across the entire cohort, variation in estimated glomerular filtration rate (eGFR) and proteinuria were independent predictors of CV risk-score improvement.

Conclusions

In this real-world CKD cohort, SGLT2 inhibitor initiation was associated with favorable changes in renal risk scores and with changes in cardiovascular risk estimates, particularly among patients with diabetes and at higher baseline risk. These findings should be interpreted as exploratory changes in predicted risk rather than as evidence of reduction in observed cardiovascular events.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Sodium-Glucose Transporter 2 InhibitorsRenal Insufficiency, ChronicCardiovascular DiseasesHumansFemaleRetrospective StudiesMiddle AgedMaleAgedRisk AssessmentTime FactorsTreatment OutcomeRisk FactorsLongitudinal StudiesGlomerular Filtration RatePropensity Score

Stichwörter der Autor:innen

Cardiovascular risk predictionChronic kidney diseaseKidney failure risk predictionSodium-glucose cotransporter-2 inhibitors

Substanzen

Sodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Nephrology, Dialysis and Kidney Transplant Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum University of Bologna, Bologna, Italy.
  • Division of Endocrinology and Diabetes Prevention and Care, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Nephrology, Dialysis and Renal Transplant Unit, Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Rende - Hospital 'SS. Annunziata', Cosenza, Italy.

ORCID-Profile: Daniele Vetrano, Michele Provenzano, Sabrina Berti, Uberto Pagotto, Gaetano La Manna

Zitieren

APA

Capelli, I., Vetrano, D., Ribichini, D., Provenzano, M., Albertini, S., Berti, S., Sanfilippo, I., Vicennati, V., Pagotto, U., La Manna, G., & Cianciolo, G. (2026). Longitudinal changes in cardiorenal risk scores after SGLT2 inhibitor initiation in patients with CKD with and without type 2 diabetes. Journal of Nephrology. https://doi.org/10.1093/joneph/aajag105

Vancouver

Capelli I, Vetrano D, Ribichini D, Provenzano M, Albertini S, Berti S, et al. Longitudinal changes in cardiorenal risk scores after SGLT2 inhibitor initiation in patients with CKD with and without type 2 diabetes. Journal of Nephrology. 2026. doi:10.1093/joneph/aajag105

BibTeX
@article{Capelli2026,
  author = {Capelli, Irene and Vetrano, Daniele and Ribichini, Danilo and Provenzano, Michele and Albertini, Sasha and Berti, Sabrina and Sanfilippo, Ilirjana and Vicennati, Valentina and Pagotto, Uberto and La Manna, Gaetano and Cianciolo, Giuseppe},
  title = {Longitudinal changes in cardiorenal risk scores after SGLT2 inhibitor initiation in patients with CKD with and without type 2 diabetes},
  journal = {Journal of Nephrology},
  year = {2026},
  doi = {10.1093/joneph/aajag105}
}
Kostenlos starten →